Read E.V.I.dently Today for current news about health policy and events, among other topics.
E.V.I.dently Today Blog
In his latest commentary for Chain Drug Review, National Pharmaceutical Council President and CEO Dan Leonard explores the health care concerns and ideas for improvement discussed at recent regional town halls hosted by the Healthcare Leadership Council and NPC.
An expert panel was convened at the ISPOR 2019 annual meeting to discuss the need for novel payment approaches to address the challenges that accompany transformative therapies.
States are getting creative about how they can meet the health care needs of their citizens, especially when it comes to curative treatments for conditions with a high rate of prevalence.
In his latest column for Specialty Pharmacy Times, National Pharmaceutical Council (NPC) President and Chief Executive Officer Dan Leonard explores recent research from the NPC and RTI Health Solutions that found biopharmaceuticals provide substantial health care benefits at modest cost — and that the reductions in mortality and morbidity in the top seven conditions causing death and disease between 1995 and 2015 show that spending on care for these conditions goes beyond cost and demonstrates value. Taken together with two other studies explored in the commentary, these research results provide powerful proof with which to challenge the conventional wisdom that all health care spending is out of control.
In his latest column for Chain Drug Review, National Pharmaceutical Council (NPC) President and Chief Executive Officer Dan Leonard highlights the importance of taking a holistic view of health care spending, rather than zeroing in on a single aspect of the health care system. The implications, he notes, are that “focusing only on the costs of a few innovative treatments doesn’t enable us to take a step back and see the bigger picture,” and that could have significant implications for health policy decisions.
In Louisiana, significant prevalence of hepatitis C cases and high treatment costs has led the state to turn to an innovative idea – using a Netflix-style subscription model to pay for curative hepatitis C medicines, in which the state will be able to access all the hepatitis C medicines it needs under a fixed cost, five-year contract. This unique payment model will be a central part of a pre-conference symposium at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting in New Orleans on Sunday, May 19 at 5:30 p.m. CT. The pre-conference symposium, sponsored by NPC, is open to all registered meeting attendees.